Kolexia
Cornet Edouard
Biologie médicale
Hôpital Côte de Nacre
Caen, France
107 Activités
357 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie à tricholeucocytes Tumeurs hématologiques Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Hyperlymphocytose Lymphomes Leucémie aigüe myéloïde Myélome multiple

Industries

Sysmex
7 collaboration(s)
Dernière en 2023
Janssen
4 collaboration(s)
Dernière en 2023
Abbvie
1 collaboration(s)
Dernière en 2022
Sanofi
1 collaboration(s)
Dernière en 2022

Dernières activités

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France.
Cancer medicine   29 janvier 2023
AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
Annual Meeting Abstracts 2022   15 novembre 2022
Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy.
Journal of cancer research and clinical oncology   27 avril 2022
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.
Cancers   10 avril 2022
Evaluation of Flow Cytometry for Cell Count and Detection of Bacteria in Biological Fluids.
Microbiology spectrum   23 février 2022
Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders.
Cancers   18 février 2022
Real Life Study on Allogeneic Hematopoietic Cell Transplantation Practice According to International Guidelines and Its Impact on Survival in Acute Myeloid Leukemia French Population
Blood   23 novembre 2021
Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
American journal of hematology   08 novembre 2021
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
Cancer medicine   22 septembre 2021